Literature DB >> 15526371

Inhibitory effect of heparin-derived oligosaccharides on secretion of interleukin-4 and interleukin-5 from human peripheral blood T lymphocytes.

Sheng-Li Ji1, Hui-Fei Cui, Feng Shi, Yan-Qing Chi, Ji-Chao Cao, Mei-Yu Geng, Hua-Shi Guan.   

Abstract

AIM: To investigate the inhibitory effect of heparin-derived oligosaccharides (Oligs) on secretion of interleukin-4 (IL-4) and interleukin-5 (IL-5) from human peripheral blood T lymphocytes (PBTLs).
METHODS: Oligs were prepared by three different heparin depolymerization methods and separated by gel filtration chromatography. PBTLs from ten adult patients with allergic eosinophilic gastroenteritis were treated with phytahematoagglutinin (PHA) and Oligs. The supernatants from the cell culture of PBTLs were harvested and subjected to the determination of IL-4 and IL-5 contents by ELISA method.
RESULTS: At the concentration of 5 microg/mL, Oligs with different Mr had different effects on the secretion of IL-4 and IL-5. The tetrasaccharide with Mr of 1,142, produced by depolymerizing heparin with hydrogen peroxide, had the strongest inhibitory effect on the secretion of IL-4. It decreased the IL-4 content from 375.6+/-39.2 ng/L (PHA group) to 12.5+/-5.7 ng/L (P<0.01). The hexasaccharide with Mr of 1,806, produced by depolymerizing heparin with beta-elimination method, had the strongest inhibitory effect on the secretion of IL-5. It decreased the IL-5 content from 289.2+/-33.4 ng/L (PHA group) to 22.0+/-5.2 ng/L (P<0.01).
CONCLUSION: The inhibitory activity of Oligs on the secretion of IL-4 and IL-5 from human PBTLs closely depends on their molecular structure, and there may be an essential structure to act as an inhibitor. The most effective inhibitors of IL-4 and IL-5 secretion are tetrasaccharides and hexasaccharides, respectively.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15526371      PMCID: PMC4576233          DOI: 10.3748/wjg.v10.i23.3490

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  59 in total

1.  Development and validation of a size exclusion chromatography method for determination of molecular masses and molecular mass distribution in low molecular weight heparin.

Authors:  H I Kristensen; E M Tromborg; J R Nielsen; J I Nielsen; K B Johansen; P B Ostergaard
Journal:  Thromb Res       Date:  1991-10-15       Impact factor: 3.944

2.  Structural determinants of heparin's growth inhibitory activity. Interdependence of oligosaccharide size and charge.

Authors:  T C Wright; J J Castellot; M Petitou; J C Lormeau; J Choay; M J Karnovsky
Journal:  J Biol Chem       Date:  1989-01-25       Impact factor: 5.157

3.  Low-dose low-molecular weight heparin (enoxaparin) is effective as adjuvant treatment in active ulcerative colitis: an open trial.

Authors:  I Dotan; A Hallak; N Arber; M Santo; A Alexandrowitz; Y Knaani; R Hershkoviz; E Brazowski; Z Halpern
Journal:  Dig Dis Sci       Date:  2001-10       Impact factor: 3.199

4.  An investigation of the association of the factor V Leiden mutation and inflammatory bowel disease.

Authors:  N Haslam; G R Standen; C S Probert
Journal:  Eur J Gastroenterol Hepatol       Date:  1999-11       Impact factor: 2.566

5.  Inhibition of selectin-mediated cell adhesion and prevention of acute inflammation by nonanticoagulant sulfated saccharides. Studies with carboxyl-reduced and sulfated heparin and with trestatin a sulfate.

Authors:  X Xie; A S Rivier; A Zakrzewicz; M Bernimoulin; X L Zeng; H P Wessel; M Schapira; O Spertini
Journal:  J Biol Chem       Date:  2000-11-03       Impact factor: 5.157

6.  Successful treatment of an acute flare of steroid-resistant Crohn's colitis during pregnancy with unfractionated heparin.

Authors:  Devang N Prajapati; Julianne R Newcomer; Jeanne Emmons; Majed Abu-Hajir; David G Binion
Journal:  Inflamm Bowel Dis       Date:  2002-05       Impact factor: 5.325

7.  Impaired response of activated mononuclear phagocytes to interleukin 4 in inflammatory bowel disease.

Authors:  S Schreiber; T Heinig; U Panzer; R Reinking; A Bouchard; P D Stahl; A Raedler
Journal:  Gastroenterology       Date:  1995-01       Impact factor: 22.682

8.  Vascular heparan sulfates may limit the ability of leukocytes to penetrate the endothelial barrier--implications for use of glucosamine in inflammatory disorders.

Authors:  M F McCarty
Journal:  Med Hypotheses       Date:  1998-07       Impact factor: 1.538

9.  Paradoxical response to heparin in 10 patients with ulcerative colitis.

Authors:  P R Gaffney; C T Doyle; A Gaffney; J Hogan; D P Hayes; P Annis
Journal:  Am J Gastroenterol       Date:  1995-02       Impact factor: 10.864

10.  Treatment of corticosteroid-resistant ulcerative colitis with heparin--a report of 16 cases.

Authors:  R C Evans; V S Wong; A I Morris; J M Rhodes
Journal:  Aliment Pharmacol Ther       Date:  1997-12       Impact factor: 8.171

View more
  1 in total

1.  Concentrations of gastric mucosal cytokines in children with food allergy and Helicobacter pylori infection.

Authors:  Elzbieta Maciorkowska; Anatol Panasiuk; Maciej Kaczmarsk
Journal:  World J Gastroenterol       Date:  2005-11-21       Impact factor: 5.742

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.